Shorts la like that also don't-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Bs777
2023-09-21

Shorts la like that also don't know

T2 Biosystems Tumbled Another 11% on Wednesday Despite FDA Approval for Anthrax and Plague Diagnostic Test

T2 Biosystems has received FDA clearance to market and sell its T2Biothreat panel. Shares of T2 Biosystems Inc. extended their losing streak to two days Wednesday despite the biotech clinching regulatory approval for a key diagnostic test.In a statement Tuesday, T2 Biosystems announced that it has received 510 clearance from the FDA for its T2Biothreat panel. The panel is a direct-from-blood molecular diagnostic test that detects six biothreat pathogens, including the organisms that cause anthrax, plague and typhus.With the FDA clearance, T2 Biosystems can immediately start marketing and selling the T2Biothreat panel in the U.S. market.Related: T2 Biosystems reaches regulatory milestone that could be a game changer, analyst says. But T2 Biosystems' stock ended Wednesday's session down 11%. The company's shares ended Tuesday's session down 26.1% to snap a two-day winning streak that saw a 65.6% gain Monday, their biggest single-day percentage gain since Sept. 11, 2019.Related: T2 Biosy

T2 Biosystems Tumbled Another 11% on Wednesday Despite FDA Approval for Anthrax and Plague Diagnostic Test

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":222199721386048,"tweetId":"222199721386048","gmtCreate":1695275152414,"gmtModify":1695275156978,"author":{"id":3579125915383486,"authorId":3579125915383486,"authorIdStr":"3579125915383486","name":"Bs777","avatar":"https://static.tigerbbs.com/55192fe99f22baba34436da27200cb77","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.14","individualDisplayEnabled":0},"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Shorts la like that also don't know&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Shorts la like that also don't know&nbsp;</p></body></html>","text":"Shorts la like that also don't know","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/222199721386048","repostId":2369110103,"repostType":2,"repost":{"id":"2369110103","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1695274214,"share":"https://www.laohu8.com/m/news/2369110103?lang=&edition=full","pubTime":"2023-09-21 13:30","market":"us","language":"en","title":"T2 Biosystems Tumbled Another 11% on Wednesday Despite FDA Approval for Anthrax and Plague Diagnostic Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2369110103","media":"Dow Jones","summary":"T2 Biosystems has received FDA clearance to market and sell its T2Biothreat panel. Shares of T2 Biosystems Inc. extended their losing streak to two days Wednesday despite the biotech clinching regulatory approval for a key diagnostic test.In a statement Tuesday, T2 Biosystems  announced that it has received 510 clearance from the FDA for its T2Biothreat panel. The panel is a direct-from-blood molecular diagnostic test that detects six biothreat pathogens, including the organisms that cause anthrax, plague and typhus.With the FDA clearance, T2 Biosystems can immediately start marketing and selling the T2Biothreat panel in the U.S. market.Related: T2 Biosystems reaches regulatory milestone that could be a game changer, analyst says. But T2 Biosystems' stock ended Wednesday's session down 11%. The company's shares ended Tuesday's session down 26.1% to snap a two-day winning streak that saw a 65.6% gain Monday, their biggest single-day percentage gain since Sept. 11, 2019.Related: T2 Biosy","content":"<html><head></head><body><p>T2 Biosystems has received FDA clearance to market and sell its T2Biothreat panel</p><p>Shares of T2 Biosystems Inc. extended their losing streak to two days Wednesday despite the biotech clinching regulatory approval for a key diagnostic test.</p><p>In a statement Tuesday, T2 Biosystems (TTOO) announced that it has received 510(k) clearance from the FDA for its T2Biothreat panel. The panel is a direct-from-blood molecular diagnostic test that detects six biothreat pathogens, including the organisms that cause anthrax, plague and typhus.</p><p>With the FDA clearance, T2 Biosystems can immediately start marketing and selling the T2Biothreat panel in the U.S. market.</p><p>But T2 Biosystems&#39; stock ended Wednesday&#39;s session down 11%. The company&#39;s shares ended Tuesday&#39;s session down 26.1% to snap a two-day winning streak that saw a 65.6% gain Monday, their biggest single-day percentage gain since Sept. 11, 2019.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6a27e12c2b2c24af056f96f3158c0cc4\" tg-width=\"606\" tg-height=\"611\"/></p><p>The FDA&#39;s decision to grant approval for the T2Biothreat panel has massive implications for the micro cap, according to Alliance Global Partners analyst Ben Haynor. &#34;We see the T2Biothreat clearance as the most important regulatory development to alter the company&#39;s near-term fortunes,&#34; he said in a note released Wednesday.</p><p>Government entities are the likeliest purchasers of the panel, according to Haynor. &#34;Should they choose to purchase T2Biothreat, we would expect the agencies to stockpile tests, which we believe could lead to large recurring orders (given the test&#39;s two-year shelf life),&#34; he said. &#34;We understand the company had identified the appropriate individuals within the government to target once the T2Biothreat panel&#39;s FDA clearance was secured, and we would expect the company to be in touch with such individuals in short order if they have not been already.&#34;</p><p>T2 Biosystems, which describes itself as a leader in the rapid detection of sepsis-causing pathogens and antibiotic-resistance genes, has been generating meme-stock-like buzz recently. The company has a market cap of $113.08 million, according to FactSet data.</p><p>Alliance Global Partners maintained its neutral rating and 18-cent stock-price target for T2 Biosystems but expects a &#34;positive bias&#34; to its rating and price target should the company start receiving T2Biothreat orders. &#34;We continue to be believers in T2&#39;s technology, but overriding near-term capital needs keep us on the sidelines,&#34; Haynor wrote. &#34;That said, provided the company can appropriately finance themselves, it appears to us the worst may be soon behind them.&#34;</p><p>T2 Biosystems is not yet cash-flow positive. &#34;We have not guided to when we will achieve cash-flow break-even, so I wouldn&#39;t do that on this call, but what I can tell you is that we have substantially strengthened our balance sheet,&#34; T2 Biosystems CEO John Sperzel said at the Sidoti Micro Cap Conference last month.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>T2 Biosystems Tumbled Another 11% on Wednesday Despite FDA Approval for Anthrax and Plague Diagnostic Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nT2 Biosystems Tumbled Another 11% on Wednesday Despite FDA Approval for Anthrax and Plague Diagnostic Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-09-21 13:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>T2 Biosystems has received FDA clearance to market and sell its T2Biothreat panel</p><p>Shares of T2 Biosystems Inc. extended their losing streak to two days Wednesday despite the biotech clinching regulatory approval for a key diagnostic test.</p><p>In a statement Tuesday, T2 Biosystems (TTOO) announced that it has received 510(k) clearance from the FDA for its T2Biothreat panel. The panel is a direct-from-blood molecular diagnostic test that detects six biothreat pathogens, including the organisms that cause anthrax, plague and typhus.</p><p>With the FDA clearance, T2 Biosystems can immediately start marketing and selling the T2Biothreat panel in the U.S. market.</p><p>But T2 Biosystems&#39; stock ended Wednesday&#39;s session down 11%. The company&#39;s shares ended Tuesday&#39;s session down 26.1% to snap a two-day winning streak that saw a 65.6% gain Monday, their biggest single-day percentage gain since Sept. 11, 2019.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6a27e12c2b2c24af056f96f3158c0cc4\" tg-width=\"606\" tg-height=\"611\"/></p><p>The FDA&#39;s decision to grant approval for the T2Biothreat panel has massive implications for the micro cap, according to Alliance Global Partners analyst Ben Haynor. &#34;We see the T2Biothreat clearance as the most important regulatory development to alter the company&#39;s near-term fortunes,&#34; he said in a note released Wednesday.</p><p>Government entities are the likeliest purchasers of the panel, according to Haynor. &#34;Should they choose to purchase T2Biothreat, we would expect the agencies to stockpile tests, which we believe could lead to large recurring orders (given the test&#39;s two-year shelf life),&#34; he said. &#34;We understand the company had identified the appropriate individuals within the government to target once the T2Biothreat panel&#39;s FDA clearance was secured, and we would expect the company to be in touch with such individuals in short order if they have not been already.&#34;</p><p>T2 Biosystems, which describes itself as a leader in the rapid detection of sepsis-causing pathogens and antibiotic-resistance genes, has been generating meme-stock-like buzz recently. The company has a market cap of $113.08 million, according to FactSet data.</p><p>Alliance Global Partners maintained its neutral rating and 18-cent stock-price target for T2 Biosystems but expects a &#34;positive bias&#34; to its rating and price target should the company start receiving T2Biothreat orders. &#34;We continue to be believers in T2&#39;s technology, but overriding near-term capital needs keep us on the sidelines,&#34; Haynor wrote. &#34;That said, provided the company can appropriately finance themselves, it appears to us the worst may be soon behind them.&#34;</p><p>T2 Biosystems is not yet cash-flow positive. &#34;We have not guided to when we will achieve cash-flow break-even, so I wouldn&#39;t do that on this call, but what I can tell you is that we have substantially strengthened our balance sheet,&#34; T2 Biosystems CEO John Sperzel said at the Sidoti Micro Cap Conference last month.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TTOO":"T2 Biosystems"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2369110103","content_text":"T2 Biosystems has received FDA clearance to market and sell its T2Biothreat panelShares of T2 Biosystems Inc. extended their losing streak to two days Wednesday despite the biotech clinching regulatory approval for a key diagnostic test.In a statement Tuesday, T2 Biosystems (TTOO) announced that it has received 510(k) clearance from the FDA for its T2Biothreat panel. The panel is a direct-from-blood molecular diagnostic test that detects six biothreat pathogens, including the organisms that cause anthrax, plague and typhus.With the FDA clearance, T2 Biosystems can immediately start marketing and selling the T2Biothreat panel in the U.S. market.But T2 Biosystems' stock ended Wednesday's session down 11%. The company's shares ended Tuesday's session down 26.1% to snap a two-day winning streak that saw a 65.6% gain Monday, their biggest single-day percentage gain since Sept. 11, 2019.The FDA's decision to grant approval for the T2Biothreat panel has massive implications for the micro cap, according to Alliance Global Partners analyst Ben Haynor. \"We see the T2Biothreat clearance as the most important regulatory development to alter the company's near-term fortunes,\" he said in a note released Wednesday.Government entities are the likeliest purchasers of the panel, according to Haynor. \"Should they choose to purchase T2Biothreat, we would expect the agencies to stockpile tests, which we believe could lead to large recurring orders (given the test's two-year shelf life),\" he said. \"We understand the company had identified the appropriate individuals within the government to target once the T2Biothreat panel's FDA clearance was secured, and we would expect the company to be in touch with such individuals in short order if they have not been already.\"T2 Biosystems, which describes itself as a leader in the rapid detection of sepsis-causing pathogens and antibiotic-resistance genes, has been generating meme-stock-like buzz recently. The company has a market cap of $113.08 million, according to FactSet data.Alliance Global Partners maintained its neutral rating and 18-cent stock-price target for T2 Biosystems but expects a \"positive bias\" to its rating and price target should the company start receiving T2Biothreat orders. \"We continue to be believers in T2's technology, but overriding near-term capital needs keep us on the sidelines,\" Haynor wrote. \"That said, provided the company can appropriately finance themselves, it appears to us the worst may be soon behind them.\"T2 Biosystems is not yet cash-flow positive. \"We have not guided to when we will achieve cash-flow break-even, so I wouldn't do that on this call, but what I can tell you is that we have substantially strengthened our balance sheet,\" T2 Biosystems CEO John Sperzel said at the Sidoti Micro Cap Conference last month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":184,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":29,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}